Search
Results
showing 1-10 of 2315
Artificial Intelligence in the HIV response: All the good stuff from AIDS2026
September 2026
An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the potential of AI to support HIV testing and prevention, including PrEP, and improve linkages to care and services, particularly in sub-Saharan Africa. “AI is becoming a new front door to HIV services,” he writes, but the analysis also shows that while most of the research was focused on feasibility and pilot implementation of AI, a significant evidence gap around health outcomes, as well as privacy, community engagement, and governance remains. He concludes that: AI is working, but trust is what makes or breaks the product; specialized tools beat generics; human-in-the-loop is becoming standard; the field needs to move from pilots to proof of outcomes; and scale depends on systems, not just models.
AVAC Comment on Proposed Reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID)
September 2026
In response to the National Institute of Health’s (NIH) proposed reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID), AVAC submitted comment to the Office of the Director of the NIH. Citing concerns of dismantling a currently unified trial oversight and support system, disruptions to trial site readiness and impacts on community engagement, and delays in funding and clinical trials, AVAC urged NIH leadership to meaningfully consider the recommendations of AVAC and many allied public health partners on the proposed restructuring.
Global Health Watch: LEN Access Pathways, NIAID Reorganization, Global Fund Report, NIH Lawsuit
September 2026
This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for greater transparency around a proposed NIAID restructuring, and a new lawsuit challenging NIH’s screening of research grants. With today as the final day to comment on the NIAID proposal, make your voice heard. And read on for a provocative Lancet commentary on the challenges of trying to reform global health architecture.
All things alimatravir (AMI)
September 2026
AVAC and partners have been engaging with Merck/MSD since the very start of the alimatravir product development program and helped conceptualize the EXPrESSIVE efficacy trial design. Building on this foundation of community-centricity, advocates can now push for AMI to be rolled out with speed, scale and equity. Since 2012, each successive PrEP introduction has gone faster than the previous one, yet the time to market and to public health impact for PrEP remains too slow. Read on for AVAC’s insights on AMI, from accelerated licensing and affordability to community priorities and meaningful engagement.
Global Health Watch: NIH-DoD Deal & NIAID Restructuring, Ebola Vaccine Progress, Gavi Funding Resumes, New US Foreign Aid Leadership
September 2026
The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring of its clinical research infrastructure. CEPI advances efforts toward a Bundibugyo Ebola vaccine amid funding gaps, while US funding for Gavi resumes and medical groups step in on vaccine guidance. And new leadership at the Department of State brings further change to the US foreign assistance system.
The Impact Report: Two Decades of Good Participatory Practice in HIV Research
September 2026
Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that halted the first ever PrEP efficacy trials, AVAC and UNAIDS led a global partnership to develop the Good Participatory Practice (GPP) Guidelines, offering systematic guidance on how to engage stakeholders throughout HIV prevention trials. Almost twenty years later, GPP is the gold standard for engagement in HIV prevention research and beyond. This edition of the Impact Report celebrates two decades of GPP, and shares how AVAC and our research and civil society partners have effectively integrated GPP into HIV prevention.
Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11
September 2026
Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement with community representatives to influence the design and implementation of the trials, with an eye toward future rollout and access planning. Leveraging expertise in community engagement and human-centered design, AVAC worked in partnership with community-based organizations on three continents to co-create communications materials for the EXPrESSIVE-11 trial – conducted among men who have sex with men (MSM), transgender, and non-binary people – that are driven by community perspectives and lived realities.
The Clinical Trial Design Academy: Equipping Advocates to Shape HIV Prevention Research Decisions and Move the Research Agenda Forward
September 2026
As clinical trial research becomes increasingly complex, and as innovative HIV prevention products advance through the pipeline, advocates with dual skillsets – deep contextual knowledge of their community’s needs and scientific and technical knowledge – are increasingly sought after to provide critical community input in research that aligns with GPP and holds researchers accountable. AVAC’s Clinical Trial Design Academy equips advocates with the scientific knowledge and skillset to influence research – from priority setting to trial design and conduct, to results dissemination.
Embedding Good Participatory Practice in PURPOSE 1
September 2026
AVAC collaborates with partners around the world to embed GPP principles in advocacy strategies and partnerships and cultivates a diverse network of advocates, civil society organizations, journalists, researchers, and implementers who champion GPP and are equipped to engage with and influence HIV clinical trial research. Gilead’s PURPOSE program investigates the efficacy of long-acting injectable lenacapavir (LEN) for PrEP among diverse populations. For PURPOSE 1 and PURPOSE 2, embedding GPP principles promoted accountability, transparency, and meaningful community engagement throughout trial design and conduct.
Topic:
showing 1-10 of 2315